IP Library Granted Patent US 12691161
Granted Patent B2
US 12691161 · App. 17/996,920 · Granted Jul 28, 2026

Mechanical and biochemical activation and control of skeletal stem cells for cartilage regeneration

Inventors: Michael T. Longaker (Atherton, CA); Charles K.F Chan (Redwood City, CA); Matthew Philip Murphy (Palo Alto, CA)
Assignee: The Board of Trustees of the Leland Stanford Junior University
A61K38/1875A61K35/545A61K38/17A61K45/06A61L27/58A61P19/02C07K16/2863A61L2300/412A61L2430/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12691161
App. No.
17/996,920
Granted
Jul 28, 2026
Kind
B2
Abstract

Methods and compositions are provided for the regeneration of articular cartilage by activating skeletal stem cells with a combination of (i) mechanical and (ii) biochemical stimulus. The mechanical stimulus can be an acute local injury. The biochemical stimulus can be a combination of an effective dose of a BMP2 activating agent and a VEGF inhibitor.

Claims (26)

1 . A method for regenerating human articular cartilage in a subject with diminished chondrogenesis, the method comprising:

activating human skeletal stem cells with a combination of (i) a mechanical stimulus, and (ii) a biochemical stimulus,

wherein the mechanical stimulus is a surgically performed microfracture procedure to bone tissue at a desired site for articular cartilage regeneration; and

wherein the biochemical stimulus is a combination of an effective dose of human BMP2 protein and a VEGF inhibitor.

2 . The method of claim 1 , wherein the biochemical stimulus is provided within 3 days of the mechanical stimulus.

3 . The method of claim 1 , wherein the VEGF inhibitor is cabozantinib.

4 . The method of claim 1 , wherein the human BMP2 protein and the VEGF inhibitor are provided in a drug delivery device.

5 . The method of claim 4 , wherein the drug delivery device comprises the human BMP2 protein and the VEGF inhibitor as the sole active agents.

6 . The method of claim 4 , wherein the drug delivery device is a biodegradable implant.

7 . The method of claim 6 , wherein the biodegradable implant is a block polymer implant.

8 . The method of claim 6 , wherein the biodegradable implant comprises poly(caprolactone) (PCL), poly(lactic acid) (PLA) or poly(lactic-co-glycolic acid) (PLGA).

9 . The method of claim 6 , wherein the biodegradable implant comprises one or more of polyethylene glycol, alginate, collagen, hyaluronic acid, cellulose, chitosan, silk, gelatin, albumin, or elastin.

10 . The method of claim 6 , wherein the biodegradable implant is a hydrogel.

11 . The method of claim 4 , wherein the drug delivery device is implanted at the site undergoing the surgically performed microfracture procedure in the absence of exogenous cells.

12 . A method for regenerating human articular cartilage in an aged human, the method comprising:

activating human skeletal stem cells with a combination of (i) a mechanical stimulus, and (ii) a biochemical stimulus,

wherein the mechanical stimulus is a surgically performed microfracture procedure to bone tissue at a desired site for articular cartilage regeneration;

wherein the biochemical stimulus is a combination of an effective dose of human BMP2 protein and a VEGF inhibitor, wherein human BMP2 protein is provided at a dose of from about 10 μg to 10 mg, and the VEGF inhibitor is provided at a dose of from about 0.1 μg to 50 mg; and

wherein the biochemical stimulus is provided within 3 days of the mechanical stimulus.

13 . The method of claim 12 , wherein the VEGF inhibitor is cabozantinib.

14 . A method for regenerating human articular cartilage in an individual with osteoarthritis, the method comprising:

activating human skeletal stem cells with a combination of (i) a mechanical stimulus, and (ii) a biochemical stimulus,

wherein the mechanical stimulus is a surgically performed microfracture procedure to bone tissue at a desired site for articular cartilage regeneration;

wherein the biochemical stimulus is a combination of an effective dose of human BMP2 protein and a VEGF inhibitor, wherein the human BMP2 protein is provided at a dose of from about 10 μg to 10 mg, and the VEGF inhibitor is provided at a dose of from about 0.1 μg to 50 mg; and

wherein the biochemical stimulus is provided within 3 days of the mechanical stimulus.

15 . The method of claim 14 , wherein the VEGF inhibitor is cabozantinib.